STAT1 as a tool for non-invasive monitoring of NK cell activation in cancer
Open Access
- 30 September 2024
- journal article
- research article
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-15
Abstract
Natural killer (NK) cells play a crucial role in immunotherapy for cancer due to their natural ability to target and destroy cancer cells. However, current methods to visualize NK cells’ activity against tumors in live organisms are limited. We introduce an imaging method that non-invasively tracks NK cell activation by cancer cells through the STAT1 protein. To achieve this, we modified NK cells to include a specific genetic sequence that binds to STAT1 when activated. These engineered NK cells (GAS-NK) demonstrate their functionality through various biological tests and analysis. Observations of changes in cancer environments and patient-derived cancer organoid models further confirm the effectiveness of this approach. Our method provides a way to monitor NK cell activity, which could improve the prediction and effectiveness of NK cell-based cancer therapies, contributing to advances in cancer treatment.Keywords
This publication has 30 references indexed in Scilit:
- Natural Killer Cells: Development, Maturation, and Clinical UtilizationFrontiers in Immunology, 2018
- Cancer immunotherapy using checkpoint blockadeScience, 2018
- The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer ImmunotherapyFrontiers in Immunology, 2017
- Molecular Imaging: A Useful Tool for the Development of Natural Killer Cell-Based ImmunotherapiesFrontiers in Immunology, 2017
- Adoptive cell transfer as personalized immunotherapy for human cancerScience, 2015
- Classification of human natural killer cells based on migration behavior and cytotoxic responseBlood, 2013
- Inborn Errors of Human JAKs and STATsImmunity, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Cancer immunotherapy comes of ageNature, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010